Introduction

Materials and Methods
• Manufacturer-specified limits of blank (LoB), detection (LoD), and quantitation (LoQ), imprecision, interference and linearity were evaluated for the ARCHITECT HoloTC assay.
• Results from the ARCHITECT HoloTC assay were compared to the Abbott AxSYM HoloTC assay (Abbott Diagnostics) by same day analysis of 98 residual serum specimens that spanned the analytical measurement range (5.0 to 128.0 pmol/L).
• 221 residual serum samples were used to compare the ARCHITECT HoloTC assay to a manual enzyme immunoassay (Active-B12 EIA, Axis-Shield Diagnostics, Dundee, Scotland, United Kingdom). Results are reportable from the lowest (0.0 pmol/L) to the highest calibrator (147.0 pmol/L).
• For both comparisons, samples below the lower limit of the ARCHITECT AMR were assigned the value of the lower limit (5.0 pmol/L); samples with results above the ARCHITECT AMR were diluted with ARCHITECT assay diluent and re-analyzed.
• Between-methods outliers were identified using StatisPro Method Evaluation Software version 2.51.00 (Analyse-it® Software Ltd. and Clinical and Laboratory Standards Institute® (CLSI), Wayne, Pennsylvania).
• Two-by-two contingency table analysis with a Yates-corrected Chi-squared test was used to determine the agreement between assays for deficiency (Excel, Microsoft Corporation, Redmond, Washington).
All reagents and testing kits for this study were provided by Axis-Shield Diagnostics, Ltd. and Abbott Diagnostics.
Results
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Vitamin B12 (cobalamin) is a necessary cofactor in methionine and succinyl-CoA metabolism. Studies estimate deficiency prevalence as high as 30% in the elderly population. Ten to thirty percent of circulating cobalamin is bound to transcobalamin (holotranscobalamin, holoTC) which can readily enter cells and is therefore considered the bioactive form. Objective: Evaluation of the analytical performance of the ARCHITECT i2000SR Active-B12 (Holotranscobalamin) assay.
Conclusions
This assay performed acceptably for LoB, LoD, LoQ, imprecision, interference and linearity.
Both method comparisons yielded comparable slopes, with ARCHITECT slightly under-recovering in comparison to the AxSYM and slightly over-recovering in comparison to the EIA. Both had similar correlation coefficients.
Medical decision point analysis indicated slight under-recovery by the ARCHITECT at the concentration of 35.0 pmol/L when compared to the EIA method.
This study determined that the ARCHITECT HoloTC assay is suitable for routine holoTC measurement using the ARCHITECT i2000SR instrument.
• Manufacturer's claims of <0.4, <1.9 and <5.0 pmol/L for LoB, LoD, and LoQ, respectively, interference, and linearity to the highest point tested (113.4 pmol/L) were verified for the ARCHITECT HoloTC assay.
• Total within-assay imprecision was 5.7% at a mean concentration of 16.2 pmol/L (SD 0.9 pmol/L), verifying the manufacturer's SD claim of ≤ 1.6 pmol/L.
• Total within-assay imprecision was 4.9% at a mean concentration of 46.7 pmol/L, verifying the manufacturer's imprecision claim of ≤8% for samples with holoTC concentrations ≥ 20 pmol/L.
• Method comparison of the ARCHITECT HoloTC to the AxSYM HoloTC produced the following Deming regression statistics: (ARCHITECT HoloTC) = 0.941(AxSYM HoloTC) + 1.2 pmol/L, Sy/x = 6.4, r = 0.947 (n=98).
• Method comparison to the Active-B12 EIA produced: (ARCHITECT HoloTC) = 1.105(Active-B12 EIA) -6.8 pmol/L, Sy/x = 11.0, r = 0.950 (n=221).
• A deficiency cutoff of 35.0 pmol/L was used to assess qualitative agreement between methods.
• The overall agreement between the ARCHITECT and AxSYM HoloTC assays for qualitative assignment of deficiency was 93%.
• The overall agreement between the ARCHITECT and EIA HoloTC assays for qualitative assignment of deficiency was 94%. 
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